‌

US Patent 10836825 Multispecific antibodies that target HIV GP120 and CD3

Patent 10836825 was granted and assigned to Gilead Sciences on November, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Gilead Sciences

Current Assignee

Gilead Sciences

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

108368250

Date of Patent

November 17, 2020

Patent Application Number

160141530

Date Filed

June 21, 2018

Patent Citations

‌

US Patent 10336818 Fc variants with altered binding to FcRn

‌

US Patent 10087239 Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody

‌

US Patent 10184000 Optimized Fc variants and methods for their generation

‌

US Patent 10584176 Fc variants with increased affinity for FcγRIIc

Patent Primary Examiner

‌

Jeffrey S. Parkin

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10836825 Multispecific antibodies that target HIV GP120 and CD3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API